Showing results (1471-1480 of 1,613) with videos related to

Sort By:
Pageof 162
JAMA Oncology|July 2, 2016
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A ReviewClaire F Friedman, Tracy A Proverbs-Singh, Michael A Postow
JAMA Oncology|February 17, 2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical TrialChiara Cremolini, Carlotta Antoniotti, Sara Lonardi, et al.
JAMA Oncology|December 23, 2017
Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer OutcomeTsuyoshi Konishi, Yoshifumi Shimada, Meier Hsu, et al.
JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.
JAMA Oncology|January 27, 2018
Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer TherapiesWei Wei, Tomoko Kurita, Kenneth R Hess, et al.
JAMA Oncology|January 27, 2018
Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any AgeLise J Estcourt, Reem Malouf, Michael F Murphy
JAMA Oncology|February 3, 2018
Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical TrialFrédéric Garban, Audrey Guyard, Helene Labussière, et al.
JAMA Oncology|November 4, 2017
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal AdenocarcinomaZhi Rong Qian, Douglas A Rubinson, Jonathan A Nowak, et al.
JAMA Oncology|November 10, 2017
Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young AdultsTalha Shaikh, Elizabeth A Handorf, Joshua E Meyer, et al.
JAMA Oncology|November 10, 2017
Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity LawsStacie B Dusetzina, Haiden A Huskamp, Aaron N Winn, et al.
Pageof 162